Login to Your Account

Attractive Enough To Buy

Vanda's Positive Phase III Data In Schizophrenia Boost Shares

By Aaron Lorenzo

Friday, December 8, 2006
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription